Show simple item record

dc.contributor.authorSobrero, A. F.
dc.contributor.authorAndre, T.
dc.contributor.authorMeyerhardt, J. A.
dc.contributor.authorGrothey, A.
dc.contributor.authorIveson, T.
dc.contributor.authorYoshino, T.
dc.contributor.authorSougklakos, I.
dc.contributor.authorMeyers, J. P.
dc.contributor.authorLabianca, R.
dc.contributor.authorSaunders, Mark P
dc.contributor.authorVernerey, D.
dc.contributor.authorYamanaka, T.
dc.contributor.authorBoukovinas, I.
dc.contributor.authorOki, E.
dc.contributor.authorGeorgoulias, V.
dc.contributor.authorTorri, V.
dc.contributor.authorHarkin, A.
dc.contributor.authorTaieb, J.
dc.contributor.authorShields, A. F.
dc.contributor.authorShi, Q.
dc.date.accessioned2020-11-16T07:49:17Z
dc.date.available2020-11-16T07:49:17Z
dc.date.issued2020en
dc.identifier.citationSobrero AF, Andre T, Meyerhardt JA, Grothey A, Iveson T, Yoshino T, et al. Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration. Journal of Clinical Oncology. 2020;38(15)en
dc.identifier.urihttp://hdl.handle.net/10541/623436
dc.description.abstractBackground: In overall population, IDEA pooled analysis did not demonstrate non-inferiority (NI) regarding 3y DFS in pts with stage III CC receiving 3m vs. 6m of adj FOLFOX/CAPOX. However, in pts treated with CAPOX (especially in low-risk pts), 3m of therapy was as effective as 6m. Results of OS and 5y DFS are reported. Methods: OS was defined as time from enrollment to death due to all causes. OS NI margin was conservatively set to be Hazard Ratio (HR) = 1.11, which is equivalent to: the maximum acceptable loss of OS efficacy, by shortening treatment to 3m, was half of the OS efficacy gained in MOSAIC trial (i.e., 2.26% absolute reduction in 5y OS rate). Pre-planned sub-group analyses included by regimen and risk group for both OS and 5y DFS. NI was to be declared if the one-sided false discovery rate adjusted (FDRa) NI p-value < 0.025. Results: With an overall median survival follow-up of 72 m (range per study, 62 to 84 m), 2584 deaths and 3777 DFS events among 12,835 pts from six trials were observed. Across 6 studies, 39.5% of pts received CAPOX (rate by study, 0% to 75.1%). Overall, the 5y OS rate was 82.4% (3m) and 82.8% (6m), with estimated OS HR of 1.02 (95% confidence interval [CI], 0.95-1.11; FDRa NI p, 0.058) and absolute 5-y OS rate difference of -0.4% (95% CI, -2.1 to 1.3%). Overall, the 5y DFS rate was 69.1% (3m) and 70.8% (6m), with estimated DFS HR of 1.08 (95%CI, 1.01-1.15, FDRa NI p, 0.22). HRs (95% CI) within subgroups see table. Conclusions: 5y OS rate reported in IDEA trials was higher than historical rates, regardless of duration of therapy. While overall survival in IDEA did not meet prior statistical assumptions for NI in overall population, the 0.4% difference in 5y OS should be placed in clinical context. OS and 5y DFS results continue to support the use of 3m adjuvant CAPOX for the vast majority of stage III colon cancer pts. This conclusion is strengthened by the substantial reduction of toxicities, inconveniencies and cost associated with shorter treatment duration.en
dc.language.isoenen
dc.titleOverall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaborationen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentOspedale Policlinico San Martino IRCCS, Genoa, Italyen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record